Among these AR antagonists, PPARγ agonists have demonstrated the potential to inhibit tumor growth by disrupting pathways involved in cellular proliferation, highlighting their therapeutic value in targeting BCa [113,134,135]. Here, PPARG is linked to neoplasm.